On May 23, 2022 Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for degenerative central nervous system diseases and advanced immuno-oncology therapeutics, reported it will release new preclinical data at two major medical conferences in June (Press release, Genuv, MAY 23, 2022, View Source [SID1234614962]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are excited to share new preclinical data for our two drug candidates, SNR1611 and GNUV201," said Heung-rok Park, Ph.D., chief technology officer of Genuv.
Details of the presentations are shown below.
Keystone Symposium: Neurodegeneration: The Biological Pathways Driving the Future of Therapeutic Development, June 5-9, Keystone, CO
Poster number: 1023
Title: Trametinib rescues neurodegeneration by TFEB-mediated activation of autophagic lysosomal function in Alzheimer’s Disease model mice
Session: Poster session 1 on June 6, 2022
Presenter: Jenny Choih, K.M.D., Ph.D.
Poster number: 2022
Title: Trametinib activates endogenous neurogenesis and recovers Alzheimer’s disease phenotype of 5XFAD
Session: Poster session 2 on June 7, 2022
Presenter: Jenny Choih, K.M.D., Ph.D.
Keystone Symposia abstracts are available at View Source
ASCO 2022 Annual Meeting, June 3-7, McCormick Place, Chicago, IL
Abstract number: e14509
Title: GNUV201, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer immunotherapy
Session: Online publication
The abstract will be released by ASCO (Free ASCO Whitepaper) on May 26, 2022, at 5:00 p.m. EDT on ASCO (Free ASCO Whitepaper).org/abstracts.